ArticleClinical kidney journal2025
Efficacy and safety of belimumab in lupus nephritis patients with nephrotic syndrome: a single-centre observational retrospective study.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Belimumab has been demonstrated to be efficient in improving the clinical outcome of patients with lupus nephritis (LN). However, evidence regarding its efficacy and safety in LN patients with nephrotic syndrome (NS) remains limited. Methods: This retrospective study included 23 LN patients (10 with NS) treated with belimumab for 18 months. The renal response, including complete renal response (CRR), partial renal response (PRR) and the primary efficacy renal response (PERR), at month 18 and safety outcomes were assessed based on the 2024 Kidney Disease: Improving Global Outcomes LN guideline. Results: Following the additional treatment with belimumab, all patients with NS achieved a renal response by month 18, with 30.0% PRR, 70.0% CRR and 80% PERR, which were comparable to those with non-NS (PRR: 30.0 versus 7.7%, Conclusions: Belimumab showed comparable effectiveness and safety in LN patients with NS, providing valuable evidence for its real-world clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.